The Aspirin For Preventing Cardiovascular Disease.
Many Americans are probably using common low-dose aspirin inappropriately in the hopes of preventing a first-time heart attack or stroke, a supplementary study suggests. Researchers found that of nearly 69000 US adults prescribed aspirin long-term, about 12 percent in all probability should not have been. That's because their odds of suffering a heart attack or work were not high enough to outweigh the risks of daily aspirin use, said Dr Ravi Hira, the persuade researcher on the study and a cardiologist at Baylor College of Medicine in Houston penis largest karneke tarike. Experts have yearn known that for people who've already had a heart attack or stroke, a daily low-dose aspirin can cut down the risk of suffering those conditions again.
Things get more complicated, though, when it comes to preventing a first-time generosity attack or stroke - what doctors call "primary prevention". In general, the benefits of aspirin psychotherapy are smaller, and for many people may not justify the downsides. "Aspirin is not a medication that comes without risks" enhancement. He notable the drug can cause serious gastrointestinal bleeding or hemorrhagic stroke (bleeding in the brain).
Still, nation sometimes dismiss the bleeding risks partly because aspirin is so familiar and readily available. The philosophy of protecting the heart by simply taking a pill might appeal to some people. "It's presumably easier to take a pill than to change your lifestyle," Hira pointed out. But based on the unfledged findings, many Americans may be making the wrong choice, Hira's team reported Jan. 12 online in the Journal of the American College of Cardiology.
The results are based on medical records for more than 68800 patients at 119 cardiology practices across the United States. The clique included forebears with apex blood pressure who had not yet developed heart disease. Overall, Hira's side found, almost 12 percent of patients seemed to be prescribed aspirin unnecessarily - their risks of determination trouble or stroke were not high enough to justify the risks of long-term aspirin use.
Showing posts with label bleeding. Show all posts
Showing posts with label bleeding. Show all posts
Friday 10 May 2019
Saturday 9 February 2019
Intrauterine Spiral Can Reduce The Severity Of Menstrual Bleeding
Intrauterine Spiral Can Reduce The Severity Of Menstrual Bleeding.
Women with sore menstrual bleeding may get some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to unripe research. British researchers found that the treated IUD was more effective at reducing the goods of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments info. Normally cast-off for contraception, the intrauterine system is sold under the brand name Mirena.
So "If women take with heavy periods and do not want to get pregnant - as the levonorgestrel intrauterine approach is a contraceptive - then having the levonorgestrel intrauterine system is a very good first-line treatment chance that does not require taking regular, daily oral medications," said the study's lead author, Dr Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England bowtrolcoloncleanse. For women who do want to get expecting taking the blood-clotting knock out tranexamic acid during periods is an interchange method of treating heavy periods.
Results of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan 10, 2013 promulgation of the New England Journal of Medicine. Heavy menstrual bleeding is a significant obstreperous for many women. About 20 percent of gynecologist assignment visits in the United States and the United Kingdom are because of heavy bleeding. There are several nonhormonal and hormonal therapy options available to reduce blood loss.
The current study compared the use of accustomed medical options - tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone unassisted - to the use of the levonorgestrel intrauterine system. The researchers randomly assigned nearly 600 women with burdened menstrual bleeding to receive either the IUD or standard medical care. They assessed recuperation using a patient-reported score on a scale designed to measure rigidity of symptoms. The scale goes from 0 to 100, with lower scores indicating more severe symptoms.
Women with sore menstrual bleeding may get some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to unripe research. British researchers found that the treated IUD was more effective at reducing the goods of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments info. Normally cast-off for contraception, the intrauterine system is sold under the brand name Mirena.
So "If women take with heavy periods and do not want to get pregnant - as the levonorgestrel intrauterine approach is a contraceptive - then having the levonorgestrel intrauterine system is a very good first-line treatment chance that does not require taking regular, daily oral medications," said the study's lead author, Dr Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England bowtrolcoloncleanse. For women who do want to get expecting taking the blood-clotting knock out tranexamic acid during periods is an interchange method of treating heavy periods.
Results of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan 10, 2013 promulgation of the New England Journal of Medicine. Heavy menstrual bleeding is a significant obstreperous for many women. About 20 percent of gynecologist assignment visits in the United States and the United Kingdom are because of heavy bleeding. There are several nonhormonal and hormonal therapy options available to reduce blood loss.
The current study compared the use of accustomed medical options - tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone unassisted - to the use of the levonorgestrel intrauterine system. The researchers randomly assigned nearly 600 women with burdened menstrual bleeding to receive either the IUD or standard medical care. They assessed recuperation using a patient-reported score on a scale designed to measure rigidity of symptoms. The scale goes from 0 to 100, with lower scores indicating more severe symptoms.
Monday 8 May 2017
To Protect From Paralysis Associated With Spinal Cord Injuries Can Oriented On Genes Therapy
To Protect From Paralysis Associated With Spinal Cord Injuries Can Oriented On Genes Therapy.
A bone up in rats is raising unexplored assumption for a treatment that might help spare people with injured spines from the paralysis that often follows such trauma. Researchers found that by instantly giving injured rats a drug that acts on a specific gene, they could halt the harmful bleeding that occurs at the site of spinal damage your vimax. That's important, because this bleeding is often a major cause of paralysis linked to spinal line injury, the researchers say.
In spinal cord injury, fractured or dislocated bone can mash or damage axons, the long branches of nerve cells that transmit messages from the body to the brain progesterone cream biovea. But post-injury bleeding at the site, called liberal hemorrhagic necrosis, can reach these injuries worse, explained study author Dr J Marc Simard, a professor of neurosurgery, pathology and physiology at University of Maryland School of Medicine in Baltimore.
Researchers have extensive been searching for ways to deal with this provisional injury. In the study, Simard and his colleagues gave a drug called antisense oligodeoxynucleotide (ODN) to rodents with spinal twine injuries for 24 hours after the injury occurred. ODN is a definitive single strand of DNA that temporarily blocks genes from being activated. In this case, the medication suppresses the Sur1 protein, which is activated by the Abcc8 gene after injury.
After uninteresting injuries, Sur1 is usually a beneficial part of the body's defense mechanism, preventing stall death due to an influx of calcium, the researchers explained. However, in the case of spinal cord injury, this defense arrangement goes awry. As Sur1 attempts to prevent an influx of calcium into cells, it allows sodium in and too much sodium can cause the cells to swell, nor'easter up and die.
In that sense, "the 'protective' procedure is a two-edged sword. What is a very good thing under conditions of moderate injury, under cold injury becomes a maladaptive mechanism and allows unchecked sodium to come in, causing the chamber to literally explode".
However, the new gene-targeted therapy might put a stop to that. Injured rats given the hallucinogen had lesions that were one-fourth to one-third the size of lesions in animals not given the drug. The animals also recovered from their injuries much better.
A bone up in rats is raising unexplored assumption for a treatment that might help spare people with injured spines from the paralysis that often follows such trauma. Researchers found that by instantly giving injured rats a drug that acts on a specific gene, they could halt the harmful bleeding that occurs at the site of spinal damage your vimax. That's important, because this bleeding is often a major cause of paralysis linked to spinal line injury, the researchers say.
In spinal cord injury, fractured or dislocated bone can mash or damage axons, the long branches of nerve cells that transmit messages from the body to the brain progesterone cream biovea. But post-injury bleeding at the site, called liberal hemorrhagic necrosis, can reach these injuries worse, explained study author Dr J Marc Simard, a professor of neurosurgery, pathology and physiology at University of Maryland School of Medicine in Baltimore.
Researchers have extensive been searching for ways to deal with this provisional injury. In the study, Simard and his colleagues gave a drug called antisense oligodeoxynucleotide (ODN) to rodents with spinal twine injuries for 24 hours after the injury occurred. ODN is a definitive single strand of DNA that temporarily blocks genes from being activated. In this case, the medication suppresses the Sur1 protein, which is activated by the Abcc8 gene after injury.
After uninteresting injuries, Sur1 is usually a beneficial part of the body's defense mechanism, preventing stall death due to an influx of calcium, the researchers explained. However, in the case of spinal cord injury, this defense arrangement goes awry. As Sur1 attempts to prevent an influx of calcium into cells, it allows sodium in and too much sodium can cause the cells to swell, nor'easter up and die.
In that sense, "the 'protective' procedure is a two-edged sword. What is a very good thing under conditions of moderate injury, under cold injury becomes a maladaptive mechanism and allows unchecked sodium to come in, causing the chamber to literally explode".
However, the new gene-targeted therapy might put a stop to that. Injured rats given the hallucinogen had lesions that were one-fourth to one-third the size of lesions in animals not given the drug. The animals also recovered from their injuries much better.
Thursday 24 March 2016
Saving Lives With Hemostatic Medicine
Saving Lives With Hemostatic Medicine.
A sedate commonly hand-me-down to prevent excess bleeding in surgeries could keep thousands of people from bleeding to death after trauma, a supplementary study suggests. The drug, tranexamic acid (TXA) is cheap, substantially available around the world and easily administered. It works by significantly reducing the rate at which blood clots recess down, the researchers explained. "When people have serious injuries, whether from accidents or violence, and when they have pitiless hemorrhage they can bleed to death.
This treatment reduces the chances of bleeding to death by about a sixth," said researcher Dr Ian Roberts, a professor of epidemiology at the London School of Hygiene and Tropical Medicine in the UK. According to Roberts, each year about 600000 bourgeoisie bleed to extermination worldwide. "So, if you could belittle that by a sixth, you've saved 100000 lives in one year".
The report, which was predominately funded by philanthropic groups and the British government, is published in the June 15 online print run of The Lancet. For the study, Roberts and colleagues in the CRASH-2 consortium randomly assigned more than 20000 trauma patients from 274 hospitals across 40 countries to injections of either TXA or placebo.
Among patients receiving TXA, the amount of extirpation from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found. In the TXA group, 14,5 percent of the patients died compared with 16 percent of the patients in the placebo group.
A sedate commonly hand-me-down to prevent excess bleeding in surgeries could keep thousands of people from bleeding to death after trauma, a supplementary study suggests. The drug, tranexamic acid (TXA) is cheap, substantially available around the world and easily administered. It works by significantly reducing the rate at which blood clots recess down, the researchers explained. "When people have serious injuries, whether from accidents or violence, and when they have pitiless hemorrhage they can bleed to death.
This treatment reduces the chances of bleeding to death by about a sixth," said researcher Dr Ian Roberts, a professor of epidemiology at the London School of Hygiene and Tropical Medicine in the UK. According to Roberts, each year about 600000 bourgeoisie bleed to extermination worldwide. "So, if you could belittle that by a sixth, you've saved 100000 lives in one year".
The report, which was predominately funded by philanthropic groups and the British government, is published in the June 15 online print run of The Lancet. For the study, Roberts and colleagues in the CRASH-2 consortium randomly assigned more than 20000 trauma patients from 274 hospitals across 40 countries to injections of either TXA or placebo.
Among patients receiving TXA, the amount of extirpation from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found. In the TXA group, 14,5 percent of the patients died compared with 16 percent of the patients in the placebo group.
Tuesday 14 January 2014
New Blood Thinner Pill For Patients With Deep Vein Thrombosis
New Blood Thinner Pill For Patients With Deep Vein Thrombosis.
A reborn anti-clotting pill, rivaroxaban (Xarelto), may be an effective, ready and safer healing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the knock out could bid a new option for these potentially life-threatening clots, which most typically produce in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual convention of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may at all change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of drug at the Academic Medical Center at the University of Amsterdam, said in an ASH announcement release. "This new treatment regimen of oral rivaroxaban can potentially deliver blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and forthright fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older painkiller warfarin and seems safer. It is also far easier to use since it does not require blood testing to patch up the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The survey was funded in part by Bayer Schering Pharma, which markets rivaroxaban most the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it improvement US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans occurrence a DVT each year. These pin clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of yearn flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The fashionable standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the word-of-mouth medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can eager unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the unrealized also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires sincere and continuous monitoring. The search for a safer and easier to administer curing option led Buller's team to analyze two sets of data: One that perforated rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
A reborn anti-clotting pill, rivaroxaban (Xarelto), may be an effective, ready and safer healing for patients coping with deep-vein thrombosis (DVT), a pair of new studies indicate. According to the research, published online Dec 4, 2010 in the New England Journal of Medicine, the knock out could bid a new option for these potentially life-threatening clots, which most typically produce in the lower leg or thigh. The findings are also slated for presentation Saturday at the annual convention of the American Society of Hematology (ASH), in Orlando, Fla.
And "These study outcomes may at all change the way that patients with DVT are treated," study author Dr Harry R Buller, a professor of drug at the Academic Medical Center at the University of Amsterdam, said in an ASH announcement release. "This new treatment regimen of oral rivaroxaban can potentially deliver blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and forthright fixed-dose approach".
Another heart expert agreed. "Rivaroxiban is at least as effective as the older painkiller warfarin and seems safer. It is also far easier to use since it does not require blood testing to patch up the dose," said cardiologist Dr Alan Kadish, currently president of Touro College in New York City.
The survey was funded in part by Bayer Schering Pharma, which markets rivaroxaban most the United States. Funding also came from Ortho-McNeil, which will market the drug in the United States should it improvement US Food and Drug Administration approval. In March 2009, an FDA admonitory panel recommended the drug be approved, but agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans occurrence a DVT each year. These pin clots - sometimes called "economy flight syndrome" since they've been associated with the immobilization of yearn flights - can migrate to the lungs to form potentially deadly pulmonary embolisms. The fashionable standard of care typically involves treatment with relatively well-known anti-coagulant medications, such as the word-of-mouth medication warfarin (Coumadin) and/or the injected medication heparin.
While effective, in some patients these drugs can eager unstable responses, as well as problematic interactions with other medications. For warfarin in particular, the unrealized also exists for the development of severe and life-threatening bleeding. Use of these drugs, therefore, requires sincere and continuous monitoring. The search for a safer and easier to administer curing option led Buller's team to analyze two sets of data: One that perforated rivaroxaban against the standard anti-clotting drug enoxaparin (a heparin-type medication), and the second which compared rivaroxaban with a placebo.
Saturday 30 November 2013
Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy
Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy.
Risk of bleeding for patients on antiplatelet analysis with either warfarin or a bloc of Plavix (clopidogrel) and aspirin is substantial, a supplementary study finds. Both therapies are prescribed for millions of Americans to preclude life-threatening blood clots, especially after a heart attack or stroke. But the Plavix-aspirin claque was thought to cause less bleeding than it actually does, the researchers say.
And "As with all drugs, these drugs come with risks; the most not joking is bleeding," said lead author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the imperil of bleeding from warfarin is well-known, the risks associated with dual psychotherapy were not well understood, she noted. "We found that the risk for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy," Shehab said. "We expected that because warfarin is prescribed much more oft-times than dual antiplatelet therapy".
However, when the researchers took the tot of prescriptions into account, the lacuna between warfarin and dual antiplatelet therapy shrank, Shehab said. "And this was worrisome," she added. For both regimens, the compute of hospital admissions because of bleeding was similar. And bleeding-related visits to crisis department visits were only 50 percent lower for those on dual antiplatelet therapy compared with warfarin, Shehab explained. "This isn't as big a imbalance as we had thought," she said.
For the study, published Monday in the Archives of Internal Medicine, Shehab's set used national databases to categorize emergency department visits for bleeding caused by either dual antiplatelet therapy or warfarin between 2006 and 2008. The investigators found 384 annual difficulty department visits for bleeding amid patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.
Risk of bleeding for patients on antiplatelet analysis with either warfarin or a bloc of Plavix (clopidogrel) and aspirin is substantial, a supplementary study finds. Both therapies are prescribed for millions of Americans to preclude life-threatening blood clots, especially after a heart attack or stroke. But the Plavix-aspirin claque was thought to cause less bleeding than it actually does, the researchers say.
And "As with all drugs, these drugs come with risks; the most not joking is bleeding," said lead author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the imperil of bleeding from warfarin is well-known, the risks associated with dual psychotherapy were not well understood, she noted. "We found that the risk for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy," Shehab said. "We expected that because warfarin is prescribed much more oft-times than dual antiplatelet therapy".
However, when the researchers took the tot of prescriptions into account, the lacuna between warfarin and dual antiplatelet therapy shrank, Shehab said. "And this was worrisome," she added. For both regimens, the compute of hospital admissions because of bleeding was similar. And bleeding-related visits to crisis department visits were only 50 percent lower for those on dual antiplatelet therapy compared with warfarin, Shehab explained. "This isn't as big a imbalance as we had thought," she said.
For the study, published Monday in the Archives of Internal Medicine, Shehab's set used national databases to categorize emergency department visits for bleeding caused by either dual antiplatelet therapy or warfarin between 2006 and 2008. The investigators found 384 annual difficulty department visits for bleeding amid patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.
Subscribe to:
Posts (Atom)